IL88531A - Cognitive enhancing compositions containing d-cycloserine - Google Patents

Cognitive enhancing compositions containing d-cycloserine

Info

Publication number
IL88531A
IL88531A IL88531A IL8853188A IL88531A IL 88531 A IL88531 A IL 88531A IL 88531 A IL88531 A IL 88531A IL 8853188 A IL8853188 A IL 8853188A IL 88531 A IL88531 A IL 88531A
Authority
IL
Israel
Prior art keywords
cycloserine
compositions containing
enhancing compositions
cognitive enhancing
cognitive
Prior art date
Application number
IL88531A
Other languages
English (en)
Other versions
IL88531A0 (en
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL88531A0 publication Critical patent/IL88531A0/xx
Publication of IL88531A publication Critical patent/IL88531A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL88531A 1987-12-01 1988-11-29 Cognitive enhancing compositions containing d-cycloserine IL88531A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (2)

Publication Number Publication Date
IL88531A0 IL88531A0 (en) 1989-06-30
IL88531A true IL88531A (en) 1993-02-21

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
IL88531A IL88531A (en) 1987-12-01 1988-11-29 Cognitive enhancing compositions containing d-cycloserine

Country Status (20)

Country Link
US (1) US4904681A (de)
EP (2) EP0319824B1 (de)
JP (2) JPH0621065B2 (de)
KR (1) KR0134198B1 (de)
AT (1) ATE68698T1 (de)
AU (4) AU622630B2 (de)
CA (1) CA1328617C (de)
DE (1) DE3865817D1 (de)
DK (1) DK173589B1 (de)
ES (1) ES2040314T3 (de)
FI (1) FI885559A0 (de)
GR (1) GR3003571T3 (de)
IE (1) IE61825B1 (de)
IL (1) IL88531A (de)
NO (1) NO885337D0 (de)
NZ (1) NZ227131A (de)
PH (1) PH26467A (de)
PT (1) PT89109B (de)
WO (1) WO1989005144A1 (de)
ZA (1) ZA888981B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
EP1389181A4 (de) 2001-04-02 2005-10-19 Panorama Res Inc Nitroxid- und nitron-antioxidationsmittel als therapeutika
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
EP2260844A1 (de) 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Kombination eines NMDA-Rezeptorantagonisten und eines selektiven Serotonin-Wiederaufnahmeinhibitoren zur Behandlung von Depression und Gemütserkrankungen
EP1660634A4 (de) * 2003-08-08 2009-02-18 Burnham Inst P16-vermittelte regulation von nmda-rezeptoren
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B8 (de) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam und bis-spiro-lactam nmda rezeptor modulatoren und deren verwendung
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
DE3865817D1 (de) 1991-11-28
ZA888981B (en) 1990-01-31
JPH01193220A (ja) 1989-08-03
AU2631988A (en) 1989-06-01
KR890009392A (ko) 1989-08-01
PT89109A (pt) 1989-12-29
IL88531A0 (en) 1989-06-30
EP0319824A1 (de) 1989-06-14
AU7746794A (en) 1995-01-05
JPH0621065B2 (ja) 1994-03-23
AU622630B2 (en) 1992-04-16
PT89109B (pt) 1993-07-30
DK669088D0 (da) 1988-11-30
ATE68698T1 (de) 1991-11-15
AU1083992A (en) 1992-05-07
ES2040314T3 (es) 1995-04-01
GR3003571T3 (de) 1993-03-16
IE61825B1 (en) 1994-11-30
WO1989005144A1 (en) 1989-06-15
KR0134198B1 (ko) 1998-04-21
EP0319824B1 (de) 1991-10-23
IE883567L (en) 1989-06-01
DK669088A (da) 1989-06-02
DK173589B1 (da) 2001-04-02
PH26467A (en) 1992-07-27
JPH05201859A (ja) 1993-08-10
NZ227131A (en) 1991-09-25
NO885337D0 (no) 1988-11-30
US4904681A (en) 1990-02-27
EP0421997A1 (de) 1991-04-17
CA1328617C (en) 1994-04-19
FI885559A0 (fi) 1988-11-30
AU2813089A (en) 1989-07-05

Similar Documents

Publication Publication Date Title
IL88531A (en) Cognitive enhancing compositions containing d-cycloserine
TW218869B (de)
DE3779053D1 (de)
EP0563345A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
IL128425A0 (en) Taxane derivatives their preparation and pharmaceutical compositions containing them
GR3007513T3 (de)
AU658296B2 (en) 7 beta-substituted-4-aza-5 alpha-cholestan-3-ones as 5 alpha-reductase inhibitors
ES8704931A1 (es) Un procedimiento para la preparacion de derivados de piridimilmidazolidiona.
NO174807C (de)
GB8728675D0 (en) Compounds & compositions
GR3004959T3 (de)
ZA888726B (en) Tert-butyl phenyl compounds useful as anti-inflammatory agents
PH25095A (en) Beta-alkylmelatonins
IL71989A0 (en) L-arginine isoxicamate and pharmaceutical compositions containing it
GB8704839D0 (en) Compound compositions
UA19097A (uk) D-1-ФЕHІЛ-2-МЕТИЛАМІHОПРОПАHОЛА 1-5,6,7-ТРИОКСИФЛАВОH-7-0-beta-D-ГЛЮКУРОHИДАТ, ЩО МАЄ ОКИСЛЮВАЛЬHУ ДІЮ ТА РОЗШИРЮЄ СУДИHИ
AU662224B2 (en) New 7beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
DK1260222T3 (da) Farmaceutiske præparater indeholdende hidtil ukendte iso-butenyl-substituerede taxaner
IE851753L (en) Aminophenol compounds.

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees